The News Review:
- … Therapeutics announces publication in Nature Medicine identi…
- Amorfix announces 2007 year end results
- Diabetes and male infertility study: Reproductive Medicine Research…
- Tm Bioscience appoints Dr. Donald Low as Chairman of Scientific…
- GW Files Sativex(R) Regulatory Submission in Canada for Cancer Pain
… Therapeutics announces publication in Nature Medicine identi…
Canada NewsWire - Canada NewsWire (press release) - Mar 26, 2008
Hassan
Salari, President and CEO. The discoveries were made possible in part through the use of a novel
SDF-1 antagonist, CTCE-0012 produced by Chemokine Therapeutics. In the Nature
Medicine publication, it was shown that CTCE-0012 is as powerful as antibodies
to CXCR4, however with the benefits of being a most closely homolog of natural
SDF-1 protein which might be used chronically. CTCE-0012 is a powerful
inhibitor of SDF-1 and prevents revascularizarion of tissues, leading to a
lower number of new blood vessels. This discovery leads the way to the
development of CTCE-0012 for diseases that are initiated through excess
vascularization, such as Macular Degeneration, etc. The article, entitled “Cytokine-mediated deployment of SDF-1 induces
revascularization through recruitment of CXCR4+ hemangiocytes” (Nature
Medicine 12(5):557-567.
Amorfix announces 2007 year end results
Canada NewsWire - Canada NewsWire (press release) - Mar 26, 2008
- Expanded the Company’s technology platform by obtaining the exclusive
worldwide rights to additional novel targets on superoxide
dismutase-1 (SOD1), which is a protein known to misfold and aggregate
in Amyotrophic Lateral Sclerosis (ALS). - Announced a research and investment collaboration agreement with
Biogen Idec which includes an option for Biogen Idec to license the
exclusive worldwide rights to Amorfix’s technology to develop and
commercialize therapeutic products directed against ALS. - Published a report in Nature Medicine, subsequent to year end,
related to Amorfix’s ALS technology which demonstrates, in animal
models, that the misfolded SOD1 protein was found in motor neurons
prior to disease symptoms and correlates to the progression of ALS. - Achieved a significant technical milestone by demonstrating that
Epitope Protection(TM) technology is able to detect protected sites
within A-beta amyloid aggregates which are formed in Alzheimer’s
disease. - Adapted its Epitope Protection(TM) technology platform to detect
sheep scrapie brain prions spiked into plasma. - Named as a “Technology Pioneer” by the World Economic Forum. - Raised gross proceeds of approximately $10,000,000 by issuing
7,694,000 units at a price of $1.
Diabetes and male infertility study: Reproductive Medicine Research…
InTheNews.co.uk - Mar 26, 2008
”
However, Professor Lewis added that it was not possible to determine from this current study whether the DNA damage caused by diabetes would have the same effect on men’s fertility as DNA damage caused by other factors such as smoking. “This is just one, relatively small study that highlights a possible concern. Further studies need to be carried out in order to understand the precise nature of the diabetes-related damage, the causal mechanisms and the clinical significance,” she said. “Given the global rise in the prevalence of diabetes, it is also vital to examine the reproductive outcomes of pregnancies fathered by diabetic men, and the prevalence of diabetes amongst men attending for infertility treatment.
Tm Bioscience appoints Dr. Donald Low as Chairman of Scientific…
Canada NewsWire - Canada NewsWire (press release) - Mar 26, 2008
“I look forward to my
involvement in advancing this truly innovative technology. Low is a Professor of Medicine and Microbiology at the University of
Toronto; Head of the Division of Microbiology in the Department of Laboratory
Medicine and Pathobiology at the University of Toronto; Medical Director of
Public Health Laboratories; and Chief of the Toronto Medical Laboratories and
Mount Sinai Hospital Department of Microbiology. Among his many appointments,
he is Chair of the Pandemic Influenza Planning Executive Committee at Mount
Sinai Hospital. The Tm SAB meets regularly to advise management on the selection and
development of new DNA-based diagnostic products and provide recommendations
on regulatory and commercialization strategies for the Company’s growing menu
of genetic tests. Tm Bioscience’s ID-Tag(TM) RVP is a proprietary, comprehensive test for
the detection of 20 of the most common strains and subtypes of respiratory
viruses, including respiratory syncytial virus A and B, influenza A (with
subtyping) and influenza B. The ID-Tag(TM) RVP is designed to play a key role
in patient management, infection control and in countering the pandemic threat
of respiratory diseases… The Company has also assumed that it will
have sufficient capital to develop and commercially roll-out and manufacture
sufficient quantities of its tests and that genetic testing for infectious
diseases will become more widespread. While the Company considers these
assumptions to be reasonable based on information currently available to it,
they may prove to be incorrect. Forward-looking statements are not guarantees of future performance and
by their nature necessarily involve risks and uncertainties that could cause
the actual results to differ materially from those contemplated by such
statements including, without limitation: the risk that the factors and
assumptions underlying the forward-looking statements may prove to be
incorrect; the difficulty of predicting regulatory approvals particularly the
timing and conditions precedent to obtaining any regulatory approval; market
acceptance and demand for new products; the availability of appropriate
genetic content and other materials required for the Company’s products; the
Company’s ability to manufacture its products on a large scale; the protection
of intellectual property connected with genetic content; the impact of
competitive products, currency fluctuations; risks associated with the
Company’s manufacturing facility; and any other similar or related risks and
uncertainties. Additional risks and uncertainties affecting the Company can be
found in the Company’s 2005 Annual report, available on SEDAR at
www. If any of these risks or uncertainties were to materialize,
actual results of the Company could vary materially from those that are
expressed or implied by these forward-looking statements.
GW Files Sativex(R) Regulatory Submission in Canada for Cancer Pain
Canada NewsWire - Canada NewsWire (press release) - Mar 26, 2008
This submission follows a formal pre-submission meeting recently held
with Health Canada outlining the evidence of effectiveness of Sativex in this
very seriously ill patient population. Dr Geoffrey Guy, GW’s Chairman, said: “This regulatory submission
represents a further step in our broad-based regulatory strategy for Sativex,
which is designed to secure approvals for this important new medicine across a
range of separate therapeutic indications in countries across the world over
the coming years. ”
GW has completed a positive Phase III study in Europe in 177 patients
with cancer pain. The trial was a multi-centre double-blind, randomized,
placebo-controlled parallel group study. Patients in the study had advanced
cancer and were experiencing pain that was not responding adequately to strong
opioid medication (e… Canada became the first
country in the world to approve Sativex, a novel prescription pharmaceutical
product derived from components of the cannabis plant shown to have
therapeutic properties. This
authorization reflects the promising nature of the clinical evidence which
will be confirmed with further studies. Earlier this year, the United States Food and Drug Administration (FDA)
accepted an Investigational New Drug (IND) Application for Sativex to enter
directly into Phase III clinical trials in the U. for the treatment of
cancer pain.
Leave a Comment